Telix Pharmaceuticals Limited

March 24, 2020 - 2 months ago
Share on twitter
Share on facebook
Share on linkedin
Share on email

Technical outlook – With only a history path going back roughly two and half years, Telix Pharmaceuticals Limited (TLX) has lost in the last five-weeks roughly half its value since prices peaked in early February 2020 at $1.68 peak.

The leading indicators Moving Average Convergence Divergence (MACD) and the Relative Strength Index (RSI) pattern currently hold to a negative outlook that suggests prices may continue in the short-term to the downside.

However, close towards the region of $0.50-60 may unleash the bulls.

Therefore, expect a rebound $1.20-25. Reassess from there.

Company Overview – Telix Pharmaceuticals Limited (TLX) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation” (MTR).

The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US).

Telix is developing a portfolio of clinical-stage oncology products that address a significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.

Share on twitter
Share on facebook
Share on linkedin
Share on email

Leave a Reply

Close Menu